✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
ASP2151 is an investigational drug.
There have been 13 clinical trials for ASP2151. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Herpes Zoster, Herpes Simplex, and Herpes Genitalis. The leading clinical trial sponsors are Maruho Europe Limited, Astellas Pharma Inc, and Maruho Co., Ltd.
There are six US patents protecting this investigational drug and sixty-seven international patents.
Recent Clinical Trials for ASP2151
|Drug-Drug Interaction Study: ASP2151 and Midazolam||Maruho Europe Limited||Phase 1|
|Drug-Drug Interaction Study: ASP2151 and Bupropion||Maruho Europe Limited||Phase 1|
|Drug-Drug Interaction Study: ASP2151 and Montelukast||Maruho Europe Limited||Phase 1|
Top disease conditions for ASP2151
Top clinical trial sponsors for ASP2151
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ASP2151||See Plans and Pricing||Viral prophylaxis treatment methods and pre-exposure prophylaxis kits||ELIAN LLC (Monrovia, CA)||See Plans and Pricing|
|ASP2151||See Plans and Pricing||Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form||Metriopharm AG (Zurich, CH)||See Plans and Pricing|
|ASP2151||See Plans and Pricing||Methods and compositions for treating herpes||Genocea Biosciences, Inc. (Cambridge, MA)||See Plans and Pricing|
|ASP2151||See Plans and Pricing||Agents for the treatment of retroviral infectious diseases||IMMUNOLOGIK GMBH (Trockenborn-Wolfersdorf, DE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ASP2151||Australia||AU2015287994||2034-07-07||See Plans and Pricing|
|ASP2151||Australia||AU2020203896||2034-07-07||See Plans and Pricing|
|ASP2151||Brazil||BR112017000285||2034-07-07||See Plans and Pricing|
|ASP2151||Canada||CA2954526||2034-07-07||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|